Dergi makalesi Açık Erişim
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd"> <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/227985</identifier> <creators> <creator> <creatorName>Busra</creatorName> <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-9863-683X</nameIdentifier> <affiliation>AKTAS</affiliation> </creator> <creator> <creatorName>Belma</creatorName> <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-0595-7237</nameIdentifier> <affiliation>ASLIM</affiliation> </creator> </creators> <titles> <title>Neuropathy In Covid-19 Associated With Dysbiosis-Related Inflammation</title> </titles> <publisher>Aperta</publisher> <publicationYear>2021</publicationYear> <subjects> <subject>COVID-19</subject> <subject>gut microbiota dysbiosis</subject> <subject>neuropathy</subject> <subject>inflammation</subject> <subject>gut–lung axis</subject> <subject>gut–brain axis</subject> </subjects> <dates> <date dateType="Issued">2021-08-30</date> </dates> <resourceType resourceTypeGeneral="Text">Journal article</resourceType> <alternateIdentifiers> <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/227985</alternateIdentifier> </alternateIdentifiers> <relatedIdentifiers> <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.3906/biy-2105-53</relatedIdentifier> </relatedIdentifiers> <rightsList> <rights rightsURI="http://www.opendefinition.org/licenses/cc-by-sa">Creative Commons Attribution Share-Alike</rights> <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights> </rightsList> <descriptions> <description descriptionType="Abstract"><p>Although COVID-19 affects mainly lungs with a hyperactive and imbalanced immune response, gastrointestinal and&nbsp;neurological symptoms such as diarrhea and neuropathic pains have been described as well in patients with COVID-19. Studies indicate&nbsp;that gut&ndash;lung axis maintains host homeostasis and disease development with the association of immune system, and gut microbiota is&nbsp;involved in the COVID-19 severity in patients with extrapulmonary conditions. Gut microbiota dysbiosis impairs the gut permeability&nbsp;resulting in translocation of gut microbes and their metabolites into the circulatory system and induce systemic inflammation which,&nbsp;in turn, can affect distal organs such as the brain. Moreover, gut microbiota maintains the availability of tryptophan for kynurenine&nbsp;pathway, which is important for both central nervous and gastrointestinal system in regulating inflammation. SARS-CoV-2 infection&nbsp;disturbs the gut microbiota and leads to immune dysfunction with generalized inflammation. It has been known that cytokines&nbsp;and microbial products crossing the blood-brain barrier induce the neuroinflammation, which contributes to the pathophysiology&nbsp;of neurodegenerative diseases including neuropathies. Therefore, we believe that both gut&ndash;lung and gut&ndash;brain axes are involved in&nbsp;COVID-19 severity and extrapulmonary complications. Furthermore, gut microbial dysbiosis could be the reason of the neurologic&nbsp;complications seen in severe COVID-19 patients with the association of dysbiosis-related neuroinflammation. This review will provide&nbsp;valuable insights into the role of gut microbiota dysbiosis and dysbiosis-related inflammation on the neuropathy in COVID-19 patients&nbsp;and the disease severity.</p></description> </descriptions> </resource>
Görüntülenme | 253 |
İndirme | 76 |
Veri hacmi | 12.0 MB |
Tekil görüntülenme | 211 |
Tekil indirme | 73 |